Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2024 Oct 17.

Published in final edited form as: N Engl J Med. 2024 Oct 16;391(15):1413–1425. doi: 10.1056/nejmoa2403365

Prevalence of clinician reported RTOG and CTCAE assessed genitourinary, gastrointestinal toxicity and erectile dysfunction at each time point assessed by treatment received (A) Prevalence of grade≥1, grade≥2 and grade≥3 RTOG Genitourinary toxicity at each time point assessed by treatment received, (B) Prevalence of grade≥1, grade≥2 and grade≥3 RTOG Gastrointestinal toxicity at each time point assessed by treatment received (C) Prevalence of grade≥1, grade≥2 and grade≥3 CTCAE Genitourinary toxicity at each late time point assessed by treatment received (D) Prevalence of grade≥1, grade≥2 and grade≥3 CTCAE Gastrointestinal toxicity at each time point assessed by treatment received, (E) Prevalence of grade≥1, grade≥2 and grade≥3 CTCAE Erectile dysfunction at each time point assessed by treatment received

Prevalence of clinician reported RTOG and CTCAE assessed genitourinary, gastrointestinal toxicity and erectile dysfunction at each time point assessed by treatment received (A) Prevalence of grade≥1, grade≥2 and grade≥3 RTOG Genitourinary toxicity at each time point assessed by treatment received, (B) Prevalence of grade≥1, grade≥2 and grade≥3 RTOG Gastrointestinal toxicity at each time point assessed by treatment received (C) Prevalence of grade≥1, grade≥2 and grade≥3 CTCAE Genitourinary toxicity at each late time point assessed by treatment received (D) Prevalence of grade≥1, grade≥2 and grade≥3 CTCAE Gastrointestinal toxicity at each time point assessed by treatment received, (E) Prevalence of grade≥1, grade≥2 and grade≥3 CTCAE Erectile dysfunction at each time point assessed by treatment received